Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Non-Current Debt (2019 - 2024)

Regen BioPharma (RGBP) has disclosed Non-Current Debt for 3 consecutive years, with $143685.0 as the latest value for Q1 2024.

  • On a quarterly basis, Non-Current Debt changed N/A to $143685.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $143685.0, a N/A change, with the full-year FY2023 number at $149614.0, changed N/A from a year prior.
  • Non-Current Debt was $143685.0 for Q1 2024 at Regen BioPharma, down from $153981.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $153981.0 in Q4 2023 to a low of $143685.0 in Q1 2024.